# Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Source: https://onco.cc/trials/nct04617522/  
OnCo record `nct04617522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

## Summary

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment. ClinicalTrials.gov record last updated 2026-06-02: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT04617522
- Phase: 1
- Setting: Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Sponsor: Gilead Sciences

## Notes

- ClinicalTrials.gov record last updated 2026-06-02: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT04617522: https://clinicaltrials.gov/study/NCT04617522

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)

---
JSON: https://onco.cc/api/v1/entities/nct04617522.json